Pesquisar
Immunoprecise Antibodies Ltd
IPAAdicionar à lista de desejos
2.070USD
0.0000.00%
Fechamento 07/02, 13:00（ET）Cotações atrasadas em 15 min
95.54MValor de mercado
PerdaP/L TTM
Mais detalhes de Immunoprecise Antibodies Ltd Empresa
ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies. It has several subsidiaries in North America and Europe including entities, such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the IPA Family). Its Contract Research Organizations (CRO) services include B cell Select; Phage Display; DeepDisplay; Abthena Bispecifics; LucinaTech Humanization; Affinity Maturation; Immunization, hybridoma, sequencing; rPEx protein manufacturing, and Cell line development. The Company utilizes custom antigen modeling, target analysis using Natural Language Processing and the HYFTTM analysis to lay the groundwork for the subsequent experimental phases.
Informações de Immunoprecise Antibodies Ltd
Código da empresaIPA
Nome da EmpresaImmunoprecise Antibodies Ltd
Data de listagemJan 30, 1987
CEODr. Jennifer Lynne Bath, Ph.D.
Número de funcionários- -
Tipo de títulosOrdinary Share
Fim do ano fiscalJan 30
EndereçoIndustrious 823 Congress Ave Suite 300
CidadeAUSTIN
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal78701
Telefone16048060626
Sitehttps://www.ipatherapeutics.com/
Código da empresaIPA
Data de listagemJan 30, 1987
CEODr. Jennifer Lynne Bath, Ph.D.
Executivos da empresa Immunoprecise Antibodies Ltd
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Jennifer Lynne Bath, Ph.D.
Dr. Jennifer Lynne Bath, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
498.12K
--
Dr. Kamil Isaev
Dr. Kamil Isaev
Independent Director
Independent Director
3.19K
--
Mr. Dirk Witters
Mr. Dirk Witters
Independent Director
Independent Director
1.95K
--
Ms. Kari Graber
Ms. Kari Graber
Vice President - Commercial Services
Vice President - Commercial Services
700.00
--
Mr. Jonathan I. (Jon) Lieber
Mr. Jonathan I. (Jon) Lieber
Director
Director
--
--
Mr. Joseph Scheffler
Mr. Joseph Scheffler
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Dr. Shuji Sato
Dr. Shuji Sato
Vice President - Innovative Solutions
Vice President - Innovative Solutions
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Jennifer Lynne Bath, Ph.D.
Dr. Jennifer Lynne Bath, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
498.12K
--
Dr. Kamil Isaev
Dr. Kamil Isaev
Independent Director
Independent Director
3.19K
--
Mr. Dirk Witters
Mr. Dirk Witters
Independent Director
Independent Director
1.95K
--
Ms. Kari Graber
Ms. Kari Graber
Vice President - Commercial Services
Vice President - Commercial Services
700.00
--
Mr. Jonathan I. (Jon) Lieber
Mr. Jonathan I. (Jon) Lieber
Director
Director
--
--
Mr. Joseph Scheffler
Mr. Joseph Scheffler
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Perguntas frequentes
Quem são os cinco principais acionistas de Immunoprecise Antibodies Ltd?
Os cinco principais acionistas de Immunoprecise Antibodies Ltd são: Dr. Jennifer Lynne Bath, Ph.D.
Quantas instituições possuem ações da Immunoprecise Antibodies Ltd (IPA)?
Em 2026Q1, 47 instituições possuíam ações da Immunoprecise Antibodies Ltd, com valor de mercado aproximado de 4.54M, representando 9.73% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em 212280.00.
Qual é a maior fonte de receita da Immunoprecise Antibodies Ltd?
Em 2026Q1, o segmento de negócios Project revenue gerou a maior receita para Immunoprecise Antibodies Ltd, totalizando 4.11M e representando 98.85% da receita total.